Novo Nordisk's pricing approaches within the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who may have accused the company of value gouging, mentioning the stark contrast involving U.S. selling prices and people in Europe and copyright. Novo Nordisk A/S is usually